Trehu EG - Search Results

1

Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy.

van den Blink B, Dillingh MR, Ginns LC, Morrison LD, Moerland M, Wijsenbeek M, Trehu EG, Bartholmai BJ, Burggraaf J. van den Blink B, et al. Among authors: trehu eg. Eur Respir J. 2016 Mar;47(3):889-97. doi: 10.1183/13993003.00850-2015. Epub 2016 Feb 11. Eur Respir J. 2016. PMID: 26869678 Free article. Clinical Trial.

2

Suppression of IL-2-induced SAA gene expression in mice by the administration of an IL-1 receptor antagonist.

Numerof RP, Sipe JD, Trehu EG, Dinarello CA, Mier JW. Numerof RP, et al. Among authors: trehu eg. Cytokine. 1992 Nov;4(6):555-60. doi: 10.1016/1043-4666(92)90019-n. Cytokine. 1992. PMID: 1292638

3

Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma.

Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Du Bois JS, et al. Among authors: trehu eg. J Clin Oncol. 1997 Mar;15(3):1052-62. doi: 10.1200/JCO.1997.15.3.1052. J Clin Oncol. 1997. PMID: 9060545 Clinical Trial.

4

Induction of circulating soluble tumour necrosis factor receptor and interleukin 1 receptor antagonist following interleukin 1 alpha infusion in humans.

Tilg H, Trehu E, Shapiro L, Pape D, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Cytokine. 1994 Mar;6(2):215-9. doi: 10.1016/1043-4666(94)90044-2. Cytokine. 1994. PMID: 8032003 Clinical Trial.

5

Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2 induced cytokine production in vitro.

Tilg H, Shapiro L, Vannier E, Poutsiaka DD, Trehu E, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. J Immunol. 1994 Mar 15;152(6):3189-98. J Immunol. 1994. PMID: 8144913

6

Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55.

Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. Blood. 1994 Jan 1;83(1):113-8. Blood. 1994. PMID: 8274730 Free article. Clinical Trial.

7

A method for the detection of erythrocyte-bound interleukin-8 in humans during interleukin-1 immunotherapy.

Tilg H, Pape D, Trehu E, Shapiro L, Atkins MB, Dinarello CA, Mier JW. Tilg H, et al. J Immunol Methods. 1993 Aug 9;163(2):253-8. doi: 10.1016/0022-1759(93)90129-u. J Immunol Methods. 1993. PMID: 8354894 Clinical Trial.

8

Possible myocardial toxicity associated with interleukin-4 therapy.

Trehu EG, Isner JM, Mier JW, Karp DD, Atkins MB. Trehu EG, et al. J Immunother Emphasis Tumor Immunol. 1993 Nov;14(4):348-51. doi: 10.1097/00002371-199311000-00015. J Immunother Emphasis Tumor Immunol. 1993. PMID: 8280718

9

A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.

McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB. McDermott DF, et al. Among authors: trehu eg. Clin Cancer Res. 1998 May;4(5):1203-13. Clin Cancer Res. 1998. PMID: 9607578 Clinical Trial.

10

Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera.

Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB. Trehu EG, et al. Clin Cancer Res. 1996 Aug;2(8):1341-51. Clin Cancer Res. 1996. PMID: 9816306 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

21 results

Search Page

Filters